Trial reportNature communications2021
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02243579 (A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome), which is not on this map. Cited by 145 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 1 pooled it
32.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome
Who cites it
145 citing papers in PubMed, 1 synthesis or guideline pooled it, 214 citations in OpenAlex.
- Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Frontiers in oncology · 2022Pooled it
- Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma.Frontiers in immunology · 2025Trial
- Trial
- Accurate and well-powered case-control analysis of spatial molecular data.Nature methods · 2026Article
- Article
- Single-cell multiomics identifies an ALDH9A1-carnitine signaling axis driving resistance of NSCLC to immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Spatial omics illuminates tumor heterogeneity.Cell reports methods · 2026Review
- Prediction of single cell expression from low-plex immunofluorescence images for guiding precision oncology.NPJ precision oncology · 2026Article
- Clinicopathological Significance of Tumor-Infiltrating T Lymphocytes and Macrophages in Primary Large B-Cell Lymphoma of Immune-Privileged Sites.Cancer research and treatment · 2026Article
- Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors.Nature biotechnology · 2026Article
- Review
- Multiregional profiling revealsScience advances · 2026Article
- Beyond CD30: Dual-Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- mosna Reveals Different Types of Cellular Interactions Predictive of Response to Immunotherapies and Survival in Cancer.Molecular & cellular proteomics : MCP · 2026Article
- Single-Cell and Spatial Omics: Methods and Applications.MedComm · 2026Review
- The CCL17-CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.Cancer immunology research · 2026Article
- Spatial proteomics in precision medicine: technologies, bioinformatics, and translational applications.Precision clinical medicine · 2026Review
- Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets.Current issues in molecular biology · 2026Review
- Cellular neighborhoods in cancer.Nature cancer · 2026Article
- AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer.Nature medicine · 2026Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Darci Phillips *Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-0804-3342
Magdalena Matusiak *Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Belén Rivero GutierrezDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Salil S BhateDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Graham L BarlowDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-9335-5414
Sizun JiangDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-6149-3142
Janos DemeterDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-7301-8055
Kimberly S SmytheCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2329-8298
Robert H PierceCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Steven P FlingCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6263-0153
Nirasha RamchurrenCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6613-9342
Martin A CheeverCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Yury GoltsevDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0003-4079-7969
Robert B WestDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Michael S KhodadoustDivision of Oncology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Youn H KimDepartment of Dermatology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Christian M SchürchDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA. christian.schuerch@med.uni-tuebingen.de.ORCID http://orcid.org/0000-0002-1792-1768
Garry P NolanDepartment of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA. gnolan@stanford.edu.ORCID http://orcid.org/0000-0002-8862-9043
Stanford University · USFred Hutch Cancer Center · USBeth Israel Deaconess Medical Center · USStanford Medicine · USUniversity Children's Hospital Tübingen · DE
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MUsing a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MSystems Biology CoreU19AI100627 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NOLAN, GARRY P · 2012 to 2021
$49.1MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MCancer Immunotherapy Trials Network Central Operations and Statistical CenterUM1CA154967 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DAVIDSON, NANCY ELLEN · 2017 to 2022
$20.7MTechnology CoreU19AI135976 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ADEREM, ALAN A · 2018 to 2022
$17.0MCancer Immunotherapy Trials Network Central Operations and Statistical CenterU01CA154967 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHEEVER, MARTIN ALEXANDER · 2010 to 2017
$16.8MThe Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2023
$13.7MProject 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GREENE, WARNER C. · 2017 to 2021
$8.5MThe Lung PCA: A Multi-Dimensional Atlas of Pulmonary PremalignancyU2CCA233238 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DUBINETT, STEVEN M., SPIRA, AVRUM E · 2018 to 2021
$7.0MStanford Tissue Mapping CenterU54HG010426 · NHGRI · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2018 to 2021
$5.1MTissue Cytokine Sequestration and Immune Regulation in AutoimmunityU01AI101984 · NIAID · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2021
$5.0MCancer Research UK 27145Cancer Research UK C27165/A29073NCI NIH HHS F32 CA233203NCI NIH HHS F99 CA212231NCI NIH HHS P30 CA015704NCI NIH HHS R33 CA183692NCI NIH HHS U01 CA154967NCI NIH HHS U2C CA233195NCI NIH HHS U2C CA233238NCI NIH HHS UM1 CA154967NHGRI NIH HHS U54 HG010426NHLBI NIH HHS R01 HL120724NHLBI NIH HHS R01 HL128173NIAID NIH HHS P01 AI131374NIAID NIH HHS T32 AI007290NIAID NIH HHS U01 AI101984NIAID NIH HHS U01 AI140498NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI100627NIAID NIH HHS U19 AI135976NIAMS NIH HHS T32 AR007422NIDDK NIH HHS UG3 DK114937
Abstract
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced CTCL patients enrolled in a pembrolizumab clinical trial (NCT02243579). We find no differences in the frequencies of immune or tumor cells between responders and non-responders. Instead, we identify topographical differences between effector PD-1
Indexed as
AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCD4-Positive T-LymphocytesFemaleHumansImmunotherapyKaplan-Meier EstimateLymphocyte ActivationLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesProgrammed Cell Death 1 ReceptorSezary SyndromeSkin NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02243579ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.